Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $0.81 per share a year ago.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. “We enter 2026 with the momentum of our continued execution,” said Steve Mahoney, President and Chief Executive Officer of Viridian. “With the veligr.
Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating
Campbell and CO Investment Adviser LLC bought a new position in shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 26,315 shares of the company's stock, valued at approximately $568,000. A number of other large investors
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 16,650 shares of the company's common stock to one new employee (the “In.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company's key priorities and anticipated catalysts for 2026. “Following another year of strong execution across our portfolio, we enter 2026 positioned for meaningful value-creation and progress,” said Steve Mahoney, President and Chief Executive Officer of.
Shares of Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have given a buy
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for veligrotug for the treatment of thyroid eye disease (TED). The application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA.
Argenx SE (NASDAQ: ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED).
Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 171,900 shares of the company's common stock to 3 new employees (the.
Fisher Asset Management LLC cut its stake in Viridian Therapeutics, Inc. (NASDAQ: VRDN) by 5.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 509,959 shares of the company's stock after selling 27,065 shares during the quarter. Fisher Asset Management LLC owned
William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA review and VRDN-003 Phase 3 data.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 88,300 shares of the company's common stock to 4 new employees (the “.
A slow period for Viridian Therapeutics, Inc. is coming to its conclusion. VRDN has recently completed financing transactions that put it on track to achieve profitability without additional dilution. Roche's Enspryng (satralizumab) has generated disappointing phase 3 results in thyroid eye disease patients, easing concerns about competition to veligrotug and VRDN-003 from the IL-6 antibody class.
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $1.15 per share a year ago.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the third quarter ended September 30, 2025. “The Viridian team continues to deliver strong results, highlighted by the successful submission of our BLA for veligrotug, completing enrollment in both pivotal c.
Viridian Therapeutics (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced the successful October submission of its BLA to the U.S. Food and Drug Administration (FDA) for veligrotug, the company's investigational therapy for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disorder characterized by.
Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) Director Fairmount Funds Management Llc purchased 454,545 shares of the stock in a transaction on Thursday, October 23rd. The shares were acquired at an average cost of $22.00 per share, with a total value of $9,999,990.00. Following the transaction, the director directly owned 3,914,458 shares in the